A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Exclusion Criteria

• •1. Patients planning to undergo radical surgery if they respond to a treatment
• •2. Patients who have non-hematological adverse events assessed as Grade \>=3 in the Common Terminology Criteria for Adverse Events ver. 4.0 in the Japanese JCOG version (CTCAE v4.0-JCOG) at the time of enrollment
• •3. Patients who have symptomatic metastases to the central nervous system or whose symptoms are hard to control
• •4. Patients who have active double cancer
• •5. Patients who have poorly controlled hypertension, or unstable angina
• •6. Patients who have a past history of congestive heart failure assessed as Class ll or higher in the New York Heart Association (NYHA) classification, or clinically significant arrhythmia requiring treatment
• •7. Patients with a past history of myocardial infarction within 6 months before enrollment
• •8. Patients who are expected to undergo major surgical treatment or who had severe injury within 28 days before enrollment, or who require major surgical treatment during the study treatment period
• •9. Patients with interstitial pneumonia which is symptomatic or requires treatment
• •10. Pregnant women, those with a positive pregnancy test, and lactating women
• •11. Patients with active systemic infection (including HCV and HBV), or who are found to be HIV-positive
• •12. Patients with hypersensitivity against pertuzumab and trastuzumab
• •13. Patients whom the investigator consider unable or unwilling to follow the protocol requirements